Lymphoma, Non-Hodgkin clinical trials

The registry lists 2,287 studies for Lymphoma, Non-Hodgkin across more than 10 countries. 286 are recruiting or about to start. 860 of them are mainly about Lymphoma, Non-Hodgkin (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13. Counting its 17 narrower conditions too, such as Lymphoma, Follicular: 6,615 studies, 1,478 open.

ClinicalTrials.gov finds 6,643 studies for Lymphoma, Non-Hodgkin. How that becomes 2,287 here

This page counts the studies the registry files under Lymphoma, Non-Hodgkin, and those it files under no condition that list Lymphoma, Non-Hodgkinthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

6,643Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−4,125Filed under a narrower condition, counted on its own pageLymphoma, Follicular 1,170 · Lymphoma, Large B-Cell, Diffuse 909 · Lymphoma, B-Cell 481 · Burkitt Lymphoma 323 · Lymphoma, Mantle-Cell 321 · Lymphoma, T-Cell, Peripheral 247 · 9 more
−81List Lymphoma, Non-Hodgkin as a condition, but the registry did not file them under itMost often written as “Indolent Non-Hodgkin Lymphoma” (9), “Mature B-cell Non-Hodgkin Lymphoma” (6), and “Indolent B-Cell Non-Hodgkin Lymphoma” (4). The registry filed 41 of them under no condition at all, and the others under other conditions only, most often Lymphoma (8) and Recurrence (8).
−150Match it another way48 name it in the title, 29 in a keyword, and 73 by a synonym or other text the search reads.
2,287The count on this page

Get an email when these change. Save the Lymphoma, Non-Hodgkin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 1,243
Terminated: 359
Recruiting: 245
Status unknown: 160
Active, not recruiting: 147
Withdrawn: 85

Phase

Phase 2: 1,002
Phase 1: 963
Phase 3: 183
Early Phase 1: 37
Phase 4: 30

Where

United States: 1,599
France: 215
China: 195
Italy: 194
Germany: 170
United Kingdom: 165

Who runs them

National Cancer Institute (NCI) (136) · Fred Hutchinson Cancer Center (70) · Memorial Sloan Kettering Cancer Center (59) · M.D. Anderson Cancer Center (58) · Hoffmann-La Roche (35) · City of Hope Medical Center (33) · Baylor College of Medicine (30) · Case Comprehensive Cancer Center (29)

What is being tested here

Drugs under test in Lymphoma, Non-Hodgkin studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Cyclophosphamide	9	9	130
Rituximab	5	30	178
Fludarabine	5	5	94
Pirtobrutinib	5	5	12
Epcoritamab	5	2	9
Tucidinostat	4	0	8
Etoposide	3	6	64
Melphalan	3	2	56
Busulfan	3	1	54
Cytarabine	3	3	36

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 18 open · Alkylating agents 14 open · Antimetabolites 11 open · Immune checkpoint inhibitors 6 open · HDAC inhibitors 4 open

Coming up

28phase 3 studies under way

126studies finish main data collection within a year7 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Feb 2027A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL · Phase 3 · Acerta Pharma BV
Feb 2027A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) · Phase 3 · Acerta Pharma BV
Mar 2027Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) · Phase 3 · Monash University
Jun 2027A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) · Phase 3 · Genmab
Aug 2027An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial · Phase 3 · AbbVie
Oct 2027A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) · Phase 3 · Loxo Oncology, Inc.
Nov 2027Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) · Phase 3 · Loxo Oncology, Inc.
Nov 2026Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma · Paolo Caimi, MD
Nov 2026A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma. · Murdoch Childrens Research Institute
Nov 2026Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant · Rigshospitalet, Denmark

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger. 68 (28%) take children under 18. 2 (1%) are for women only and 0 (0%) for men only; 10 (4%) take healthy volunteers.

Recruiting studies that take each age, of 245
Age	Women	Men
10	53 (22%)	53 (22%)
18	239 (98%)	237 (97%)
30	227 (93%)	225 (92%)
40	220 (90%)	218 (89%)
50	220 (90%)	218 (89%)
65	220 (90%)	218 (89%)
75	200 (82%)	198 (81%)
85	160 (65%)	158 (64%)

Across all 2,287 studies, recruiting or not: 29% stop at 75 or younger and 15% at 65; 24% take children; <1% are for women only and <1% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Lymphoma, Non-Hodgkin studies take

Of 286 phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 55 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	55 mo38–75 · 286 studies	47 mo37–70 · 163 studies	57 mo39–80 · 123 studies
Phase 1/2	72 mo50–104 · 135 studies	65 mo40–103 · 69 studies	75 mo53–110 · 66 studies
Phase 2	65 mo41–104 · 223 studies	45 mo30–77 · 50 studies	67 mo43–111 · 173 studies
Phase 3	68 mo43–86 · 58 studies	64 mo43–84 · 41 studies	—
Interventional, no phase	50 mo22–113 · 66 studies	—	50 mo29–123 · 60 studies
Observational	120 mo37–… · 71 studies	—	159 mo34–… · 57 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 15, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 2,287. Browse all 2,287 → or search them.